✨
AI Summary
- Kurma Partners closed BioFund IV at €215m, falling short of its target.
- This gap highlights a structural issue limiting European biotech's scale.
- The fund focuses on early-stage investment in European biotech.
Guests on This Episode
AG
Amanda Gett-Chaperot
1 podcast appearance